EGRX Eagle Pharmaceuticals Inc.

56.43
-0.42  -1%
Previous Close 56.85
Open 56.98
Price To book 4.92
Market Cap 842027186
Shares 14,921,623
Volume 36,592
Short Ratio 11.10
Av. Daily Volume 305,997

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171187411
  2. 8-K - Current report 171185025
  3. 8-K - Current report 171160006
  4. 8-K - Current report 171102750
  5. 8-K - Current report 171093264

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.
PEMFEXY,
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
CRL issued July 26, 2017. Additional trial required.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Ryanodex
Malignant hyperthermia - cancer

Latest News

  1. Eagle Pharmaceuticals, Inc. to Present at 29th Annual Piper Jaffray Healthcare Conference
  2. Barron's After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals Plunges
  3. Edited Transcript of EGRX earnings conference call or presentation 8-Nov-17 1:30pm GMT
  4. See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
  5. Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : November 10, 2017
  6. Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : November 9, 2017
  7. Eagle Pharmaceuticals posts 3Q profit
  8. Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results
  9. Eagle Pharmaceuticals, Inc. to Host Earnings Call
  10. Eagle Pharmaceuticals, Inc. to Present at Jefferies 2017 London Healthcare Conference
  11. Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017
  12. Eagle Pharma gets tentative FDA approval for Lilly's Alimta version
  13. FDA tentatively approves Eagle Pharma's cancer drug
  14. Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute
  15. ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 24, 2017
  16. Eagle Pharmaceuticals Announces New Patent for RYANODEX
  17. 3 Biotech Values in a Fully Valued Market
  18. Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : October 11, 2017

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171187411
  2. 8-K - Current report 171185025
  3. 8-K - Current report 171160006
  4. 8-K - Current report 171102750
  5. 8-K - Current report 171093264
  6. 8-K - Current report 171082237
  7. SC 13G - Statement of acquisition of beneficial ownership by individuals 171049994
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018492
  9. 8-K - Current report 171016396
  10. 8-K - Current report 17983743